All In Biotech

Drug Trial Radar · NCT00820053

A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection

Eastern Hepatobilliary Surgical Hospital

Last checked: Nov 20, 2026Latest source record: Apr 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

450

Actual

Start

Jan 2009

Primary completion

Dec 2009

Study completion Dec 2010

Sponsor

Lead sponsor
Eastern Hepatobiliary Surgery HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group. The time to recurrence ,the overall survival as well as the incidence of complications after therapy was observed to confirm the role of adjuvant TACE.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • epirubicin and lipiodolDrug

    using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 2010

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eastern hepatobilliary surgery hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.